Matt Holdren

Matt Holdren is an experienced professional in toxicology and nonclinical development, currently serving as Vice President of Toxicology at Septerna since September 2024. Prior to this role, Holdren held the position of Vice President of Nonclinical Development at Lycia Therapeutics from November 2022 to September 2024, and served as Vice President of Preclinical Development at Tenaya Therapeutics from December 2021 to November 2022. Holdren's career includes significant roles at Genentech, including Toxicologist, Project Team Lead, and Senior Director of Safety Assessment from December 2013 to December 2021, as well as Senior Research Investigator in Drug Safety Evaluation at Bristol-Myers Squibb (June 2011 - December 2013). Earlier experience encompasses work as a Senior Scientist in Toxicology and Research Associate in Pharmacology at ZymoGenetics. Holdren holds a Ph.D. and a B.S. from the University of Washington.